ES2168309T3 - Efectos neuroprotectores primario y secundario de la flupirtina en las enfermedades neurodegenerativas. - Google Patents

Efectos neuroprotectores primario y secundario de la flupirtina en las enfermedades neurodegenerativas.

Info

Publication number
ES2168309T3
ES2168309T3 ES94926828T ES94926828T ES2168309T3 ES 2168309 T3 ES2168309 T3 ES 2168309T3 ES 94926828 T ES94926828 T ES 94926828T ES 94926828 T ES94926828 T ES 94926828T ES 2168309 T3 ES2168309 T3 ES 2168309T3
Authority
ES
Spain
Prior art keywords
neuroprotecting
flupirtine
primary
effects
neurodegenerative diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94926828T
Other languages
English (en)
Inventor
Michael Schwarz
Gabriela Pergande
Jurgen Engel
Bernd Nickel
Heinz Ulrich
Stefan Szelenyi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meda Pharma GmbH and Co KG
Original Assignee
Viatris GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viatris GmbH and Co KG filed Critical Viatris GmbH and Co KG
Application granted granted Critical
Publication of ES2168309T3 publication Critical patent/ES2168309T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Confectionery (AREA)

Abstract

EL EFECTO ANTAGONISTICO A LA NMDA DE LA FLUPIRTINA PERMITE LA PREPARACION DE MEDICAMENTOS PARA EL TRATAMIENTO DE LA ISQUEMIA CEREBRAL, DE LOS TRASTORNOS NEURODEGENERATIVOS, DE LAS LESIONES TRAUMATICAS DEL CEREBRO Y DE LA MEDULA ESPINAL, ATAQUES EPILEPTICOS Y OTRAS ENFERMEDADES.
ES94926828T 1993-08-17 1994-08-10 Efectos neuroprotectores primario y secundario de la flupirtina en las enfermedades neurodegenerativas. Expired - Lifetime ES2168309T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4327516A DE4327516A1 (de) 1993-08-17 1993-08-17 Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin

Publications (1)

Publication Number Publication Date
ES2168309T3 true ES2168309T3 (es) 2002-06-16

Family

ID=6495312

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94926828T Expired - Lifetime ES2168309T3 (es) 1993-08-17 1994-08-10 Efectos neuroprotectores primario y secundario de la flupirtina en las enfermedades neurodegenerativas.

Country Status (27)

Country Link
US (1) US5721258A (es)
EP (1) EP0716602B1 (es)
JP (1) JPH09501664A (es)
KR (1) KR100341952B1 (es)
CN (1) CN1086291C (es)
AT (1) ATE210442T1 (es)
AU (1) AU694447B2 (es)
BG (1) BG62430B1 (es)
BR (1) BR9407293A (es)
CA (1) CA2169718C (es)
CZ (1) CZ289040B6 (es)
DE (2) DE4327516A1 (es)
DK (1) DK0716602T3 (es)
EE (1) EE03204B1 (es)
ES (1) ES2168309T3 (es)
HR (1) HRP940464A2 (es)
HU (1) HU227765B1 (es)
IL (1) IL110681A (es)
NO (1) NO309842B1 (es)
NZ (1) NZ273292A (es)
PT (1) PT716602E (es)
RU (1) RU2166318C2 (es)
SK (1) SK283330B6 (es)
UA (1) UA43351C2 (es)
WO (1) WO1995005175A1 (es)
YU (1) YU49215B (es)
ZA (1) ZA946176B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
DE19541405A1 (de) * 1995-11-07 1997-05-15 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen
DE19625582A1 (de) * 1996-06-27 1998-01-02 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen die mit einer unphysiologisch hohen Zellsterberate einhergehen
EP1034783B1 (en) * 1997-10-27 2004-12-15 Sumitomo Pharmaceuticals Company, Limited Amide derivatives for the treatment of retinal neurodegenerative disorders
AU1359801A (en) * 1999-11-05 2001-06-06 Vela Pharmaceuticals Inc. Methods and compositions for treating reward deficiency syndrome
WO2001039760A2 (en) * 1999-12-01 2001-06-07 Duke University Method of treating batten disease
US6821995B1 (en) 1999-12-01 2004-11-23 Duke University Method of treating batten disease
DE10327674A1 (de) 2003-06-20 2005-01-05 Awd.Pharma Gmbh & Co. Kg Injizierbare Darreichungsform von Flupirtin
DE10328260A1 (de) * 2003-06-23 2005-01-27 Schmidt, K.-G., Dr. med. Flupirtine-Präparat
CN1917876A (zh) * 2003-12-16 2007-02-21 Cns生物有限公司 方法和组合物
EP1831170A4 (en) * 2004-12-14 2009-10-14 Astrazeneca Ab SUBSTITUTED AMINOPYRIDINES AND THEIR USE
EP1688141A1 (en) 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
US20060258708A1 (en) * 2005-05-16 2006-11-16 Andrulis Peter J Jr Method for treating Parkinson's disease and other neurological diseases
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
DE102011006425A1 (de) 2010-03-31 2011-10-06 Awd.Pharma Gmbh & Co. Kg Pharmazeutische Zubereitung und deren Verwendung
DE102010030053A1 (de) 2010-06-14 2011-12-15 Awd.Pharma Gmbh & Co.Kg Injizierbare Darreichungsform von Flupirtin
EP3027188A4 (en) * 2013-07-31 2017-03-01 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and flupirtine
US11369593B2 (en) * 2017-07-14 2022-06-28 Texas Tech University System Functionalized pyridine carbamates with enhanced neuroprotective activity
DE102017007385A1 (de) 2017-08-02 2019-02-07 Christoph Hoock Maleatfreie feste Arzneimittelformen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4481205A (en) * 1980-09-13 1984-11-06 Degussa Aktiengesellschaft 2-Amino-3-carbethoxyamino-6-(p-fluoro-benzylamino)-pyridine-maleate
ATE25078T1 (de) * 1982-10-27 1987-02-15 Degussa 2-amino-3-acylamino-6-benzylamino-pyridinderivate mit anti-epileptischer wirkung.
DE3337593A1 (de) * 1982-10-27 1984-05-03 Degussa Ag, 6000 Frankfurt 2-amino-3-acylamino-6-benzylamino-pyridin-derivate mit antiepileptischer wirkung
NO860825L (no) * 1985-03-23 1986-09-24 Degussa Fremgangsmaate til fremstilling av 2-amino-3-nitro-6-(4-fluor-benzylamino)-pyridin samt 2-amino-3-karbetoksyamino-6-(4-fluor-benzylamino)-pyridin.
IN172468B (es) * 1990-07-14 1993-08-14 Asta Medica Ag

Also Published As

Publication number Publication date
WO1995005175A1 (en) 1995-02-23
HU227765B1 (en) 2012-02-28
HUT75650A (en) 1997-05-28
RU2166318C2 (ru) 2001-05-10
NZ273292A (en) 1999-09-29
UA43351C2 (uk) 2001-12-17
KR100341952B1 (ko) 2003-04-11
CZ46596A3 (en) 1996-05-15
BR9407293A (pt) 1996-10-01
IL110681A0 (en) 1994-11-11
CA2169718A1 (en) 1995-02-23
YU51294A (sh) 1998-05-15
HU9600355D0 (en) 1996-04-29
NO960607L (no) 1996-02-15
CN1086291C (zh) 2002-06-19
CZ289040B6 (cs) 2001-10-17
KR960703591A (ko) 1996-08-31
DE4327516A1 (de) 1995-02-23
SK283330B6 (sk) 2003-06-03
PT716602E (pt) 2002-05-31
DE69429435D1 (de) 2002-01-24
HRP940464A2 (en) 1997-06-30
CA2169718C (en) 2002-11-12
BG100356A (bg) 1996-07-31
ZA946176B (en) 1995-03-20
AU694447B2 (en) 1998-07-23
JPH09501664A (ja) 1997-02-18
EP0716602B1 (en) 2001-12-12
DK0716602T3 (da) 2002-03-25
EP0716602A1 (en) 1996-06-19
NO960607D0 (no) 1996-02-15
AU7652894A (en) 1995-03-14
CN1129399A (zh) 1996-08-21
DE69429435T2 (de) 2002-06-13
YU49215B (sh) 2004-11-25
IL110681A (en) 1999-08-17
US5721258A (en) 1998-02-24
EE03204B1 (et) 1999-08-16
NO309842B1 (no) 2001-04-09
ATE210442T1 (de) 2001-12-15
SK21496A3 (en) 1997-01-08
BG62430B1 (bg) 1999-11-30

Similar Documents

Publication Publication Date Title
ES2168309T3 (es) Efectos neuroprotectores primario y secundario de la flupirtina en las enfermedades neurodegenerativas.
HN1998000027A (es) Arilsulfonamidas y analagos
MX9205681A (es) Aminometil-cromanos, procedimiento para su fabricacion y medicamento que los contiene.
ES2188586T3 (es) Utilizacion de inhibidores del complemento para la preparacion de un medicamento para la profilaxis y terapia de enfermedades inflamatorias intestinales y de la piel, asi como purpura.
ES2164111T3 (es) Empleo del principio activo flupirtina para la preparacion de un medicamento para combatir espasmos musculares.
AR048912A1 (es) Inmunoglobulinas anti-nogo
MX9301348A (es) Nuevos compuestos que tienen actividad farmacologica, proceso para su preparacion y composicion farmaceutica que los comprende.
ES2058592T3 (es) El uso de sustancias activas fisiologicamente para la fabricacion de medicamentos para enfermedades cerebrales y neuronales.
AR020762A1 (es) El uso de carnitina y resveratrol para producir una composicion para la prevencion o el tratamiento terapeutico de los trastornos cerebrales provocados porel envejecimiento y el uso de drogas neurotoxicas
ES2093257T3 (es) Utilizacion de torasemida para la preparacion de medicamentos destinados al tratamiento de edemas cerebrales.
UY24717A1 (es) Nuevo tratamiento
ES2134284T3 (es) Pirido-pirimidindionas, procedimiento para su preparacion y su empleo como medicamentos.
FI954614A (fi) Imidatsolokinoksalinonijohdannaiset EAA-antagonisteina
MX9307048A (es) Derivados de piridazinoquinazolona, y composicion farmaceutica que los contiene.
AR008083A1 (es) Composiciones farmaceuticas y el uso de compuestos para preparar medicamentos para tratar desordenes del snc.
ES2144857T3 (es) Utilizacion de derivados benzonaftalenicos para la fabricacion de medicamentos destinados para el tratamiento de las enfermedades del sistema nervioso.
ES2188742T3 (es) Trapidil para uso en la terapia de cuadros patologicos influenciables por la inmunomodulacion.
AR026804A1 (es) Utilizacion de la enoxaparina para la preparacion de un medicamento para tratar la isquemia cerebral
ES2147576T3 (es) Utilizacion del efaroxan y de sus derivados para la preparacion de un medicamento destinado al tratamiento de la enfermedad de parkinson.
SE8703308D0 (sv) Therapeutic agent for the treatment of disorders associated with cerebral ischemia
AR006870A1 (es) Esteres de acido fosfonico para el tratamiento de trastornos funcionales del cerebro y la depresion, procedimiento para la preparacion de los mismos,medicamentos que los contienen, uso de los compuestos para la preparacion de medicamentos
ES2161745T3 (es) Utilizacion de la trimetazidina para la obtencion de medicamentos destinados para el tratamiento de los trastornos relacionados con la nefrotoxicidad de la ciclosporina a.
FR2757512B1 (fr) Utilisation de benzoylalkyl-1-1,2,3,6-tetrahydropyridines
NO984430D0 (no) Anvendelse av en inhibitor av Na+/H+-utveksler for fremstilling av medikament for behandling av profylakser av sykdommer i sentralnervesystemet
ES2085411T3 (es) Uso de heptastigmina en la terapia de ictus cerebral.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 716602

Country of ref document: ES